Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Increased CSF HVA response to arecoline challenge in Alzheimer's disease.

Literature DB >> 1281646

Increased CSF HVA response to arecoline challenge in Alzheimer's disease.

N Pomara¹, M Stanley, P A LeWitt, M Galloway, R Singh, D Deptula.
1. Lafayette Clinic, Detroit, MI.

Abstract

The effects of the muscarinic agonist, arecoline, on the concentration of homovanillic acid (HVA) in the cerebrospinal fluid of patients with Alzheimer's disease (AD) and controls were examined. Patients and controls received intravenous infusions of arecoline and a lumbar puncture was performed four hours after the infusion began. Arecoline induced a significant increase in the concentration of HVA in cerebrospinal fluid of Alzheimer's disease patients (p < .01) but not in controls. The differential HVA response to a muscarinic agonist in Alzheimer's disease is suggestive of an alteration in muscarinic receptor response. This finding may have potential implications for the pathophysiology and treatment of Alzheimer's disease.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1992 PMID： 1281646 DOI： 10.1007/BF01250518

Source DB: PubMed Journal: J Neural Transm Gen Sect

68 in total

1. Increased muscarinic receptor messenger RNA in Alzheimer's disease temporal cortex demonstrated by in situ hybridization histochemistry.

Authors: P J Harrison; A J Barton; A Najlerahim; B McDonald; R C Pearson
Journal: Brain Res Mol Brain Res Date: 1991-01

2. Nicotinic and muscarinic cholinergic receptors in Alzheimer's disease and related disorders.

Authors: P J Whitehouse; K J Kellar
Journal: J Neural Transm Suppl Date: 1987

3. Homovanillic acid and 5-hydroxyindoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia and parkinsonism.

Authors: C G Gottfries; I Gottfries; B E Roos
Journal: J Neurochem Date: 1969-09 Impact factor: 5.372

1. Pathological Increases in Neuronal Hyperactivity in Selective Cholinergic and Noradrenergic Pathways May Limit the Efficacy of Amyloid-β-Based Interventions in Mild Cognitive Impairment and Alzheimer's Disease.

Authors: Nunzio Pomara; Davide Bruno
Journal: J Alzheimers Dis Rep Date: 2018-10-03

1 in total

Increased CSF HVA response to arecoline challenge in Alzheimer's disease.

1. Increased muscarinic receptor messenger RNA in Alzheimer's disease temporal cortex demonstrated by in situ hybridization histochemistry.

2. Nicotinic and muscarinic cholinergic receptors in Alzheimer's disease and related disorders.

3. Homovanillic acid and 5-hydroxyindoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia and parkinsonism.

4. Presynaptic cholinergic dysfunction in patients with dementia.

5. Cerebrospinal fluid flow and iodide 131 transport in the spinal subarachnoid space.

6. Denervation, supersensitivity and muscarinic receptors in the cat iris.

7. Metabolic fate of l-[14C] DOPA in cerebrospinal fluid and blood plasma of humans.

8. Decreased muscarinic receptor binding in cerebral cortex and hippocampus in Alzheimer's disease.

9. Memory and cognitive function in man: does the cholinergic system have a specific role?

10. Muscarinic and nicotinic cholinergic binding sites in Alzheimer's disease cerebral cortex.

1. Pathological Increases in Neuronal Hyperactivity in Selective Cholinergic and Noradrenergic Pathways May Limit the Efficacy of Amyloid-β-Based Interventions in Mild Cognitive Impairment and Alzheimer's Disease.